US 12,109,253 B2
Use of IGFBP7 for treating malaria
Wenn-Chyau Lee, Singapore (SG); and Laurent Renia, Singapore (SG)
Assigned to Agency for Science, Technology and Research, Singapore (SG)
Appl. No. 17/426,756
Filed by AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH, Singapore (SG)
PCT Filed Jan. 30, 2020, PCT No. PCT/SG2020/050043
§ 371(c)(1), (2) Date Jul. 29, 2021,
PCT Pub. No. WO2020/159444, PCT Pub. Date Aug. 6, 2020.
Claims priority of application No. 10201900872X (SG), filed on Jan. 30, 2019.
Prior Publication US 2022/0096604 A1, Mar. 31, 2022
Int. Cl. A61K 38/36 (2006.01); A61K 31/137 (2006.01); A61K 31/155 (2006.01); A61K 31/357 (2006.01); A61K 31/366 (2006.01); A61K 31/4706 (2006.01); A61K 31/4709 (2006.01); A61K 31/506 (2006.01); A61K 31/635 (2006.01); A61K 31/65 (2006.01); A61K 38/18 (2006.01); A61P 33/06 (2006.01)
CPC A61K 38/36 (2013.01) [A61K 31/137 (2013.01); A61K 31/155 (2013.01); A61K 31/357 (2013.01); A61K 31/366 (2013.01); A61K 31/4706 (2013.01); A61K 31/4709 (2013.01); A61K 31/506 (2013.01); A61K 31/635 (2013.01); A61K 31/65 (2013.01); A61K 38/18 (2013.01); A61P 33/06 (2018.01)] 14 Claims
 
1. A composition comprising (i) insulin growth factor binding protein 7 (IGFBP7) and (ii) a Von Willebrand Factor (VWF), and/or a thrombospondin-1 (TSP-1), and/or one or more other anti-malarial drugs.